iRhythm Q3 revenue rises 14.9% to $221.6 million; raises 2026 revenue guidance
iRhythm reported third-quarter 2026 revenue of $221.6 million, up 14.9% from a year earlier, and raised its full-year 2026 revenue guidance to $890 million to $895 million. The GAAP net loss widened to $29.9 million, or $0.90 per share, from $5.2 million, or $0.16 per share, a year earlier, and the quarter included $49.8 million in litigation settlement charges.
Key points
- Q3 2026 revenue of $221.6 million, up from $192.9 million in Q3 2025; gross margin was 74.2%
- GAAP net loss of $29.9 million, or $0.90 per diluted share, versus a net loss of $5.2 million, or $0.16 per share, in Q3 2025
- Litigation settlements of $49.8 million were recorded in the quarter
- 2026 revenue guidance raised to $890 million to $895 million, including about $16 million from the VitalConnect acquisition closed October 5, 2026
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.